Treatment of arterial hypertension in patients who are indicated for combination therapy;
To reduce the risk of cardiovascular disease and mortality in patients with arterial hypertension and left ventricular hypertrophy.
Hypersensitivity to losartan and sulfonamide derivatives (such as hydrochlorothiazide) or to any of the components of the drug;
Untreated hypokalemia or hypercalcemia;
Severe hepatic insufficiency; cholestasis or obstruction of the bile ducts;
Refractory hyponatremia;
Severe renal insufficiency (creatinine clearance < 30 ml / min);
Anuria;
Pregnancy and lactation;
Age under 18 (efficacy and safety not established).
Co-administration with aliskiren in patients with diabetes mellitus.
The drug contains lactose, so patients with a rare hereditary pathology of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption should not take this drug.
With caution: bilateral renal artery stenosis or single kidney artery stenosis, hypovolemic conditions (including diarrhea, vomiting), hyponatremia (increased risk of hypotension in patients on a low-salt or salt-free diet), hypochloremic alkalosis, hypomagnesemia, hypokalemia, connective tissue diseases (including systemic lupus erythematosus), diabetes mellitus, gout, bronchial asthma, severe allergic history, hyperuricemia, hypercalcemia, mild to moderate liver failure, aortic or mitral valve stenosis, obstructive hypertrophic cardiomyopathy, symptomatic hyperuricemia/gout.